US9624241, Example 47A;7-(3,5-dimethyl-1,2-oxazol-4-yl)-N,N-dimethyl-2-oxo-11-phenyl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-triene-10-carboxamide
CAS
——
化学式
C23H22N4O4
mdl
——
分子量
418.452
InChiKey
SPQJLQHQYSZDNH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
2.5
重原子数:
31
可旋转键数:
3
环数:
5.0
sp3杂化的碳原子比例:
0.26
拓扑面积:
87.9
氢给体数:
1
氢受体数:
5
文献信息
TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
申请人:INCYTE CORPORATION
公开号:US20160046650A1
公开(公告)日:2016-02-18
The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
The present invention relates to tricyclic heterocycles of Formula (I):
which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
本发明涉及式 (I) 的三环杂环:
它们是 BET 蛋白如 BRD2、BRD3、BRD4 和 BRD-t 的抑制剂,可用于治疗癌症等疾病。
TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR